Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 8/20 | 0.54 |
| ▸ | ORAI1 | Q96D31 | 8/20 | 0.54 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | IL2 | P60568 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14158774 | 0.89 | STIM1 (0.61) | STIM1ORAI1ORAI2SCN9APDE2A | |
| SCHEMBL14239239 | 0.83 | STIM1 (0.55) | STIM1ORAI1ORAI2SCN9APDE2A | |
| SCHEMBL14887559 | 0.82 | STIM1 (0.64) | STIM1ORAI1ORAI2SCN9APDE2A | |
| SCHEMBL14887550 | 0.79 | STIM1 (0.54) | STIM1ORAI1ORAI2SCN9APDE2A | |
| SCHEMBL14240001 | 0.77 | STIM1 (0.66) | STIM1ORAI1ORAI2 | |
| SCHEMBL14240087 | 0.75 | STIM1 (0.46) | STIM1ORAI1IL2 | |
| SCHEMBL15003812 | 0.73 | STIM1 (0.46) | STIM1ORAI1 | |
| SCHEMBL14150229 | 0.71 | STIM1 (0.80) | STIM1ORAI1ORAI2SCN9APDE2A | |
| SCHEMBL14882374 | 0.70 | STIM1 (0.72) | STIM1ORAI1ORAI2SCN9AIL2 | |
| SCHEMBL14226017 | 0.70 | STIM1 (1.00) | STIM1ORAI1ORAI2SCN9AIL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130143927-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2012170951-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143927-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885ORAI2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.